TheranosticTrials.org
Clarity Pharmaceuticals

Clinical Trial · NCT04023331

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial

Overview

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Sponsor

Clarity Pharmaceuticals

Phase

Phase 1/2

Contacts

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

ClinicalTrials.gov

NCT04023331

Eligibility

Inclusion

  • • Known high-risk neuroblastoma OR previously intermediate-risk neuroblastoma that has relapsed
  • • Karnofsky or Lansky performance status ≥50;
  • • Adequate liver function
  • • Adequate renal function

Exclusion

  • • Any other active malignancy, or a history of prior malignancy within the past 3 years;
  • • Participants with disease of any major organ system that would compromise their ability to tolerate therapy
  • • History of cardiac failure
  • • Participants who are on hemodialysis
  • • Any medical condition which the Investigator feels may interfere with the procedures or evaluations of the study

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…